I. Chronic Toxicity Summary

**Inhalation reference exposure level**

0.00004 µg/m$^3$ (40 pg/m$^3$)

**Oral reference exposure level**

1 x $10^{-8}$ mg/kg/day (10 pg/kg/day)

**Critical effect(s)**

Increased mortality, decreased weight gain, depression of erythroid parameters, increased urinary excretion of porphyrins and delta-aminolevulinic acid, increased serum activities of alkaline phosphatase, gamma-glutamyl transferase and glutamic-pyruvic transaminase, gross and histopathological changes in the liver, lymphoid tissue, lung and vascular tissues in rats.

**Hazard index target(s)**

Alimentary system (liver); reproductive system; development; endocrine system; respiratory system; hematopoietic system

II. Physical and Chemical Properties (HSDB, 1995; 1999)

**Description**

All are white crystalline powders at 25°C.

**Molecular Formula**

C$_{12}$H$_4$C$_{14}$O$_2$ (TCDD)

**Molecular Weight**

321.97 g/mol (TCDD)

**Density**

1.827 g/ml (estimated for TCDD)

**Boiling Point**

412.2°C (estimated for TCDD)

**Melting Point**

305-306°C (TCDD)

**Vapor Pressure**

1.52 x $10^{-9}$ torr at 25°C (TCDD)

**Solubility**

In water: 19.3 ng/L at 22°C (TCDD)

**Log K$_{ow}$**

6.15-7.28 (6.8 for TCDD)

**Log K$_{oc}$**

6.0-7.39

**Henry’s Law Constant**

8.1 x $10^{-5}$ ATM-m$^3$/mol
III. Major Uses and Sources

The chlorinated dioxins and furans are generated as by-products from various combustion and chemical processes. PCDDs are produced during incomplete combustion of chlorine containing wastes like municipal solid waste, sewage sludge, and hospital and hazardous wastes. Various metallurgical processes involving heat, and burning of coal, wood, petroleum products and used tires for energy generation also generate PCDDs. Chemical manufacturing of chlorinated phenols (e.g., pentachlorophenol), polychlorinated biphenyls (PCBs), the phenoxy herbicides (e.g., 2,4,5 T), chlorinated benzenes, chlorinated aliphatic compounds, chlorinated catalysts and halogenated diphenyl ethers are known to generate PCDDs as a by-product under certain conditions. While manufacture of many of these compounds and formulations has been discontinued in the United States, continued manufacture elsewhere in the world combined with use and disposal of products containing PCDD by-products results in the inadvertent release of PCDDs into the environment. Industrial and municipal processes in which naturally occurring phenolic compounds are chlorinated can produce PCDDs; the best example is chlorine bleaching of wood pulp in the manufacture of paper products. Additionally, municipal sewage sludge has been documented to occasionally contain PCDDs and PCDFs. Annual statewide industrial emissions from facilities reporting under the Air Toxics Hot Spots Act in California based on the most recent inventory were estimated to be 0.123 pounds of 2,3,7,8-TCDD, 0.244 pounds of 1,2,3,4,7,8-hexachlorodibenzodioxin and lesser amounts of other polychlorinated dibenzodioxins and dibenzofurans (CARB, 1999).

IIIa. 2,3,7,8 Tetrachlorodibenzo-p-dioxin Toxic Equivalents

2,3,7,8-Tetrachlorodibenzo-p-dioxin is considered the most potent congener of the polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) families of compounds. Potency of PCDD and PCDF congeners correlates with the binding affinity to the cytosolic Ah receptor. Structure activity studies have demonstrated that optimal biological activity and Ah-receptor binding requires congeners with a planar conformation and chlorines at the corners of the molecule at the 2,3,7,8 positions (Poland and Knutson, 1982; Safe, 1986). Chlorines at both ortho positions in these molecules (i.e., positions 1 and 9) sterically hinder a planar conformation that lessens the congeners’ biological activity. Thus only 15 of 210 different PCDDs and PCDFs congeners possess significant biological activity based on chlorines in the 2,3,7,8 positions and some degree of planar conformation (Safe, 1986; U.S. EPA 1989). These include two tetrachloro-congener: 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzofuran; three pentachloro congeners: 1,2,3,7,8-pentachlorodibenzo-p-dioxin, 1,2,3,7,8-pentachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran; seven hexachloro congeners: 1,2,3,4,7,8 or 1,2,3,6,7,8 or 1,2,3,7,8,9-hexachlorodibenzo-p-dioxins and hexachlorodibenzofurans and 2,3,4,6,7,8-hexachlorodibenzofuran; and three heptachloro congeners: 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin, 1,2,3,4,6,7,8-heptachlorodibenzofuran and 1,2,3,4,7,8,9-heptachlorodibenzofuran (U.S. EPA, 1989). The structures of the dibenzo-p-dioxins and dibenzofurans along with their numbering schemes are shown in Figure 1. Toxic equivalents are calculated relative to the most potent congener, 2,3,7,8-tetrachlorodibenzo-p-dioxin, and are determined based on structure activity studies examining relative affinity for the...
Ah receptor as well as on relative toxicity of different congeners. Values for the international system of toxic equivalents are provided in Table 1 (U.S. EPA, 1989).

**Table 1.** International Toxic Equivalency Factors (I-TEFs) for PCDDs and PCDFs Chlorinated in the 2,3,7, and 8 Positions. (U.S. EPA 1989.)

<table>
<thead>
<tr>
<th>Compound</th>
<th>I-TEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mono-, Di-, and Tri-CDDs and CDFS</td>
<td>0</td>
</tr>
<tr>
<td>TetraCDD</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8-substituted</td>
<td>1.0</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>PentaCDD</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8-substituted</td>
<td>0.5</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>HexaCDD</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8-substituted</td>
<td>0.1</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>HeptaCDD</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8-substituted</td>
<td>0.01</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>OctaCDD</td>
<td></td>
</tr>
<tr>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>TetraCDF</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8</td>
<td>0.1</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>PentaCDF</td>
<td></td>
</tr>
<tr>
<td>1,2,3,7,8-PentaCDF</td>
<td>0.05</td>
</tr>
<tr>
<td>2,3,4,7,8-PentaCDF</td>
<td>0.5</td>
</tr>
<tr>
<td>others</td>
<td>0</td>
</tr>
<tr>
<td>HexaCDF</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8-substituted</td>
<td>0.1</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>HeptaCDF</td>
<td></td>
</tr>
<tr>
<td>2,3,7,8-substituted</td>
<td>0.01</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
</tr>
<tr>
<td>OctaCDF</td>
<td></td>
</tr>
<tr>
<td>0.001</td>
<td></td>
</tr>
</tbody>
</table>

1 CDD designates chlorinated dibenzo-p-dioxin
2 CDF designates chlorinated dibenzofuran
Figure 1. Structures of the Dibenzo-p-dioxins and Dibenzofurans

IV. Effects of Human Exposure

The information available on possible chronic toxic effects in humans is complicated by the relative insensitivity of epidemiological studies, the limited ability of case studies of exposed individuals to establish cause and effect relationships, the heterogeneous nature of human populations, the broad spectrum of exposures to other toxic agents in the human environment, and the episodic exposure of many of the exposed human populations which have been studied (e.g., Seveso, Italy). As a result, a limited number of effects have been associated with exposure to dioxins in humans. The meaning of these effects in terms of toxicity in most cases remains to be clarified. The majority of information comes from cross-sectional medical studies.

Chloracne is the most widely recognized effect of exposure to 2,3,7,8-TCDD and TCDD-like PCDDs and PCDFs. Chloracne is a persistent condition, which is characterized by comedones, keratin cysts and inflamed papules and is seen after acute and chronic exposure to various chlorinated aromatic compounds (Moses and Prioleau, 1985). Other dermal effects include hyperpigmentation and hirsutism or hypertrichosis (Jirasek et al., 1974; Goldman, 1972; Suskind et al., 1953; Ashe and Suskind, 1950); both appear to resolve themselves more quickly over time than chloracne, making them more of an acute response rather than a chronic response (U.S. EPA, 1994a). Epidemiological data available for 2,3,7,8-TCDD have not allowed a determination of the threshold dose required for production of chloracne (U.S. EPA, 1994b). Case studies suggest that there may be a relationship between 2,3,7,8-TCDD exposure and hepatomegaly (Reggiani, 1980; Jirasek et al., 1974; Suskind et al., 1953; Ashe and Suskind, 1950) and hepatic enzyme changes (Mocarelli et al., 1986; May, 1982; Martin 1984; Moses et al., 1984). Nevertheless, cross sectional epidemiological studies of trichlorophenol (TCP) production workers (Suskind and Hertzberg., 1984; Bond et al., 1983; Moses et al., 1984; Calvert et al. 1992), Vietnam veterans (Centers for Disease Control Vietnam Experience Study, 1988; Roegner et al., 1991) and Missouri residents (Webb et al., 1989; Hoffman et al., 1986)
found little evidence for an association between exposure and hepatomegaly suggesting that this is not a chronic response. There is a consistent pattern of increased levels of serum gamma glutamyl transferase in populations exposed to 2,3,7,8-TCDD, which is presumably of hepatic origin (Mocarelli, 1986; Caramaschi et al., 1981, May; Martin, 1984; Moses et al., 1984; Calvert et al., 1992; Centers For Disease Control Vietnam Experience Study, 1988). Two cross sectional studies have associated diabetes and elevated fasting serum glucose levels with relatively high serum 2,3,7,8-TCDD levels (Sweeney et al., 1992; Roegner et al., 1991). However other studies provided mixed results (Moses et al., 1984; Centers for Disease Control Vietnam Experience Study, 1988; Ott et al., 1993). TCDD has been associated with effects on reproductive hormonal status in males. The likelihood of abnormally low testosterone levels was 2 to 4 times greater in individuals with serum 2,3,7,8-TCDD levels above 20 pg/ml (Egeland et al. 1994) and increased serum levels of luteinizing hormone and follicle stimulating hormone have been documented (Egeland et al., 1994). A number of other effects have been reported that were either not seen as chronic effects or effects seen long term in only one population of exposed persons. These include elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase), pulmonary disorders, neurologic disorders, and changes in porphyrin metabolism and kidney disorders (U.S. EPA, 1994c). Areas in which there is presently insufficient information to draw solid conclusions include effects on the circulatory system, reproductive effects, immunological effects, effects on metabolism and handling of lipids, and on thyroid function (U.S. EPA, 1994c). Recent findings in Rhesus monkeys have shown 2,3,7,8-TCDD to cause endometriosis (Reier et al., 1993) and epidemiological studies are currently underway to determine if there is an association between TCDD exposure and endometriosis in human populations exposed by the Seveso accident.

Potential effects of a toxicant on normal fetal development include fetal death, growth retardation, structural malformations and organ system dysfunction. Evidence for all of these responses has been seen in human populations exposed to dioxin-like compounds. In these poisoning episodes populations were exposed to a complex mixture of halogenated aromatic hydrocarbons contained within PCBs, PCDFs and PCDDs mixtures thus limiting the conclusions that could be drawn from the data. In the Yusho and Yu-Cheng poisoning episodes, human populations consumed rice oil contaminated with PCBs, PCDFs and PCDDs. Yu-Cheng women experienced high perinatal mortality in hyperpigmented infants born to affected mothers (Hsu et al. 1985). This occurred in women with overt signs of toxicity (chloracne) (Rogan, 1982) and Rogan notes that, when there is no sign of toxicity in the mother, the likelihood of fetotoxicity appears to lessen considerably in the infants. Signs of toxicity from dioxin like compounds were absent in infants born to mothers apparently not affected in the Seveso, Italy and Times Beach, Missouri, incidents (Reggiani, 1989; Hoffman and Stehr-Green, 1989), which supports Rogan’s conclusion. There was an increased incidence of decreased birth weight in infants born to affected mothers in the Yusho and Yu-Cheng incidents suggesting fetal growth retardation (Wong and Huang, 1981; Law et al., 1981; Lan et al., 1989; Rogan et al., 1988). The structural malformation, rocker bottom heel, was observed in Yusho infants (Yamashita and Hayashi, 1985) making this malformation a possible result of exposure to dioxin-like compounds. Nevertheless, it is unknown if these compounds produce malformations in humans. Evidence for possible organ system dysfunction in humans comes from a study of Yu-Cheng children which found that children exposed in utero experienced delays in attaining developmental milestones, and exhibited neurobehavioral abnormalities (Rogan et al., 1988)
suggesting involvement of CNS function. Dysfunction of dermal tissues is noted in exposed infants of the Yusho and Yu-Cheng incidents and is characterized by hyperpigmentation of the skin, fingernails, and toenails, hypersecretion of the meibomian glands, and premature tooth eruption (Taki et al., 1969; Yamaguchi et al., 1971; Funatsu et al., 1971; Wong and Huang, 1981; Hsu et al., 1985; Yamashita and Hayashi, 1985; Rogan et al., 1988; Rogan, 1989; Lan et al., 1989).

V. Effects of Animal Exposure

The toxicity to laboratory animals encompasses a number of areas including changes in energy metabolism manifested as wasting syndrome, hepatotoxicity, effects on tissue of epithelial origin, various endocrine effects, effects on vitamin A storage and use, immune system effects and reproductive and developmental toxicity. The limited number of chronic studies available do not examine all these endpoints. Therefore subchronic exposures are included here in order to provide a more complete coverage of potential chronic toxic effects of these compounds.

Wasting syndrome is one of the most broadly occurring toxic effects. The wasting syndrome is characterized by loss of adipose tissue and lean muscle mass and is produced in all species and strains tested, but there are differences in sensitivity (U.S. EPA 1994d; Peterson et al., 1984; Max and Silbergeled, 1987). Numerous studies have not yet established the mechanism of wasting syndrome (U.S. EPA, 1994e). Hepatotoxicity is also seen in all species tested, but there is considerable variation in species sensitivity (U.S. EPA, 1994d). TCDD induces hyperplasia and hypertrophy of liver parenchymal cells. Morphological and biochemical changes in the liver include increased SGOT and SGPT, induction of microsomal monoxygenases and proliferation of the smooth endoplasmic reticulum, porphyria, increased regenerative DNA synthesis, hyperlipidemia, hyperbilirubinemia, hypercholesterolemia, hyperproteinemia, degenerative and necrotic changes, mononuclear cell infiltration, multinucleated giant hepatocytes, increased numbers of mitotic figures, and parenchymal cell necrosis (U.S. EPA, 1994d; WHO/IPCS, 1989). Epithelial effects seen include chloracne (rabbit ear and the hairless mouse) (Jones and Krizek, 1962; Schwetz et al., 1973) and hyperplasia and/or metaplasia of gastric mucosa, intestinal mucosa, the urinary tract, the bile duct and the gall bladder (U.S. EPA 1994f). TCDD exposure results in endocrine like effects including epidermal growth factor like effects such as early eye opening and incisor eruption in the mouse neonate (Madhukar et al., 1984), glucocorticoid like effects such as involution of lymphoid tissues (U.S. EPA, 1994g; Sunahara et al., 1989), alteration in thyroid hormone levels and in some cases thyroid hormone like effects (WHO/IPCS, 1989; Rozman et al., 1984), decreases in serum testosterone and dihydrotestosterone (Mittler et al., 1984; Keys et al., 1985; Moore and Peterson, 1985), and changes in arachidonic acid metabolism and prostaglandin synthesis (Quilley and Rifkind, 1986; Rifkind et al., 1990). TCDD is known to decrease hepatic vitamin A storage (Thunberg et al., 1979). TCDD and other dioxin like PCDDs and PCDFs are potent suppressors of both cellular and humoral immune system function, characteristically producing thymic involution at low doses and involution of other lymphoid tissues at higher doses (U.S. EPA 1994h).

In animal studies there is a large body of information available documenting both developmental and reproductive toxicity of 2,3,7,8-TCDD and other PCDDs and PCDFs. These compounds are

Chlorinated Dibenzo-p-Dioxins and Chlorinated Dibenzofurans
acutely toxic to early life stages of fish and birds with fish being most sensitive (LD$_{50}$ of 0.4 µg/kg for rainbow trout sac fry eggs and LD$_{50}$ of 34 ng/kg for lake trout eggs); some species of birds are also relatively sensitive (LD$_{50}$ of 0.25 µg/kg for chicken eggs) (Peterson et al., 1993). 2,3,7,8-TCDD has been documented to increase the incidence of prenatal mortality in a number of species of laboratory animals including the Rhesus monkey, Guinea pig, rabbit, rat, hamster, and mouse (Peterson et al., 1993). Exposure to 2,3,7,8-TCDD during gestation produces a characteristic set of fetotoxic responses in most laboratory animals which includes: thymic hypoplasia, subcutaneous edema, and decreased growth (Peterson et al., 1993). More species specific responses include cleft palate formation in the mouse at doses below maternal toxicity (Moore et al., 1973; Smith et al., 1976; Couture et al., 1990), intestinal hemorrhage in the rat (Sparschu et al., 1971), hydronephrosis in the mouse and hamster (Moore et al., 1973; Smith et al., 1976; Couture et al., 1990; Birnbaum et al., 1989; Olson et al., 1990), and extra ribs in the rabbit (Giavini et al., 1982). Female rats have also been found to be affected by perinatal exposure to 2,3,7,8-TCDD with clefting of the clitoris, incomplete or absent vaginal opening and a smaller vaginal orifice after a dose of 1 µg/kg to the mother on day 15 of gestation (Gray et al., 1993).

A number of effects on adult reproductive function are seen in male animals exposed in utero to 2,3,7,8-TCDD. TCDD reduces plasma androgen levels in the adult male rat and perinatal exposure decreases spermatogenesis, spermatogenic function and reproductive capability, feminizes male sexual behavior, and feminizes male gonadotrophic function (LH secretion) (Mably et al., 1991; Mably et al., 1992a,b,c). Evidence suggests that these effects are the result of impaired sexual differentiation of the CNS, which in male rats is dependent on exposure of the developing brain to testosterone.

There are numerous studies detailing the effects of the PCDDs, PCDFs and other dioxin like compounds, however a large number of these studies were conducted as either acute or subchronic exposures, studies in which it is unlikely that body burdens had reached steady state levels. Detailed below are three chronic studies that were considered in the setting of a chronic toxicity exposure level.

The most definitive study of chronic toxicity in rats is that of Kociba et al. (1978). This study involved the administration of 2,3,7,8-TCDD in the diet at doses of 1 ng/kg/day, 10 ng/kg/day, and 100 ng/kg/day to groups of 50 male and 50 female Sprague Dawley rats for two years. A group of 86 male and 86 female rats received diet with solvent vehicle alone and served as controls. The following observations (excluding carcinogenic effects) were seen at the 100 ng/kg/day dose: increased mortality, decreased weight gain, depressed erythroid values, increased urinary excretion of porphyrins and delta-aminolevulinic acid, and increased serum activities of alkaline phosphatase, gamma-glutamyl transferase, and glutamic-pyruvic transaminase. Histopathologic changes were noted in the liver, lymphoid tissue, respiratory and vascular tissues. The primary ultrastructural change in the liver was proliferation of the rough endoplasmic reticulum. At the 10 ng/kg/day dose the severity of toxic symptoms was less than that of the 100 ng/kg/day dose and included increased urinary excretion of porphyrins in females as well as liver and lung lesions. The 1 ng/kg/day dose produced no discernible significant toxic effects. Interpretation of this study by the authors was that the 1 ng/kg/day dose was a NOAEL.
Two chronic toxicity studies are available in the mouse. The first is a one year study conducted by Toth et al. (1979) using male Swiss mice administered weekly oral doses of 7, 700, and 7000 ng/kg/day. In this study 2,3,7,8-TCDD administration resulted in amyloidosis and dermatitis in 0 of 38 control animals, 5 of 44 animals receiving 7 ng/kg/day, 10 of 44 animals receiving 700 ng/kg/day and 17 of 43 animals receiving 7,000 ng/kg/day. The other study was from the NTP 1982 gavage study (NTP, 1982) in B6C3F1 mice. This study employed groups of 50 male and 50 female mice. The males received doses of 0, 10, 50, and 500 ng/kg/week by gavage for two years while female mice received doses of 0, 40, 200, and 2000 ng/kg/week by gavage for two years. No adverse effects were seen at the lowest doses tested in each sex, which correspond to NOAELs of approximately 1.4 and 6 ng/kg/day for males and females, respectively. Neither chronic toxicity study in mice reported data on enzyme activity.

VI. Derivation of Chronic Reference Exposure Level (REL)

- **Study:** Kociba et al. (1978)
- **Study population:** Sprague-Dawley rats of both sexes (50/treatment group/sex)
- **Exposure method:** Continuous dietary exposure starting at seven weeks of age for 2 years
- **Critical effects:** Increased mortality, decreased weight gain, depression of hematologic measures, increased urinary excretion of porphyrins and delta-aminolevulinic acid, increased serum activities of alkaline phosphatase, gamma-glutamyl transferase and glutamic-pyruvic transaminase, gross and histopathological changes in the liver, lymphoid tissue, lung and vascular tissues
- **Observed LOAEL:** 210 ppt in diet (0.01 µg/kg/day)
- **Observed NOAEL:** 22 ppt in diet (0.001 µg/kg/day)
- **Exposure continuity:** Continuous exposure via the diet
- **Exposure duration:** 2 years
- **Subchronic uncertainty factor:** 1
- **LOAEL uncertainty factor:** 1
- **Interspecies uncertainty factor:** 10
- **Intraspecies uncertainty factor:** 10
- **Cumulative uncertainty factor:** 100
- **Oral reference exposure level:** 10 pg/kg/day
- **Route-to-route extrapolation:** 3,500 µg/m^3 per mg/kg/day
- **Inhalation reference exposure level:** 40 pg/m^3 (0.00004 µg/m^3)

The data available for chronic toxic effects in humans have a number of limitations. Some studies did not determine the body burden of compounds necessary to estimate dose.; The Yusho and Yu-Cheng poisoning episodes have uncertainty because exposure was to complex mixtures of halogenated aromatic hydrocarbons rather than to individual congeners. And epidemiological
studies and case studies have limitations in determining cause and effect relationships. Therefore, an animal study was chosen for determination of a NOAEL/LOAEL. The study chosen for use was that of Kociba et al. (1978), based on the duration of the study (2 years), the number of animals employed (50 per treatment group per sex), testing of both sexes, a dose range, which spanned from an apparent NOAEL to severe hepatic effects including carcinogenic effects, a complete histopathological examination of all organ systems, examination of urinary excretion of porphyrins and delta-aminolevulinic acid, and determination of serum activities of alkaline phosphatase, gamma-glutamyl transferase, and glutamic-pyruvic transaminase. The elevation of human serum values for gamma-glutamyl transferase is one of the consistently seen chronic responses in exposed human populations and reflects changes in liver biochemistry. Thus the examination of markers of liver toxicity also altered in animal models of chronic toxicity make the Kociba study an appropriate choice for detecting potential chronic toxic effects of 2,3,7,8-TCDD in humans. The NOAEL in the Kociba et al. (1978) study was determined to be 1 ng/kg body weight/day. For the purposes of determining the REL the 1 ng/kg/day dose was considered to be a NOAEL based upon the observations of Kociba et al. (1978).

VII. Data Strengths and Limitations for Development of the REL

NOAELs from a number of other studies compare favorably with the 1 ng/kg/day NOAEL. These include the NOAEL from the NTP (1982) study in B6C3F1 mice and the NOEL for enzyme induction in rats and marmosets calculated by Neubert (1991) of 1 ng/kg. Furthermore the 1 ng/kg/day NOAEL is lower than the LOAELs observed by Toth et al. (1979) of 7 ng/kg/day in mice and by Schantz et al. (1978) of 2.3 ng/kg/day in rhesus monkeys. Current exposure assessments for 2,3,7,8-TCDD and other dioxin-like compounds including the PCBs, PCDDs, and PCDFs estimate that the average daily background dose in the U.S. is 3-6 pg TEQ/kg/day (U.S. EPA 1994i) also placing the REL close to background exposures. The REL of 10 pg/kg/day should be protective of chronic effects on liver function and avoid significant increases in exposure over the background level of human exposure.

The strengths of the inhalation REL include the availability of chronic exposure data from a well-conducted study with histopathological analysis, the observation of a NOAEL, and the demonstration of a dose-response relationship. Major areas of uncertainty are the lack of adequate human exposure data and the lack of chronic inhalation exposure studies.
VIII. References

Ashe WF, and Suskind RR. 1950. Reports on chloracne cases, Monsanto Chemical Co., Nitro, West Virginia, October 1949 and April 1950. Cincinnati, OH: Department of Environmental Health, College of Medicine, University of Cincinnati (unpublished).


U.S. EPA. 1994h. ibid. Vol 1:3-4-1.


